Lumentum falls despite stronger earnings as Marvell agrees an all-stock takeover
Earnings results
- EPS
GAAP $3.54; adjusted $4.57 per share
- Revenue
$1.263 billion for Q1 FY2027
- Guidance
Q2 sales $1.575–1.625B; adjusted EPS $5.90–6.20
Earnings and the stock move
On November 2, Lumentum and Marvell announced a definitive all-stock acquisition agreement signed November 1. Each Lumentum common share would receive 4.500 Marvell shares, so the consideration moves with the buyer’s share price. The announced $1,132 reference value uses October 28 unaffected prices and is not a fixed cash offer. The deal remains subject to approvals, with closing expected in the first half of 2028. Lumentum also released fiscal first-quarter 2027 results early: revenue of $1.26 billion, GAAP profit per share of $3.54 and adjusted profit per share of $4.57. Both developments frame the current trading decline; no isolated causal attribution to the earnings numbers is asserted.
Q1 FY2027 earnings recap
Lumentum traded at $767.18, down 8.75% during trading on November 2, after stronger earnings and a signed all-stock takeover agreement with Marvell.
- Marvell agreed to exchange 4.5 of its shares for each Lumentum share. The deal’s value therefore changes with Marvell’s share price; the announced $1,132 reference value is not a cash payment or guaranteed floor.
- The companies put the deal’s initial enterprise value, including debt, at $115 billion. They expect it to close in the first half of 2028, subject to shareholder and regulatory approvals.
- Lumentum sells lasers and optical systems that move data through AI and telecom networks. Combining them with Marvell’s chips could help customers design the electrical and optical connections together.
- For the quarter ended September 26, sales reached $1.26 billion. Adjusted EPS, or profit per share, was $4.57; reported GAAP profit was $3.54 per share.
- Management issued next-quarter sales guidance of $1.58–1.625 billion and adjusted profit of $5.9–6.20 per share. Manufacturing capacity and delivering new products remain important execution tests.
- The completed October 30 chart closed at $840.7, below its 20-day and 50-day averages near $922. Earlier lows around $736–756 provide a reference area; they are not a guaranteed floor.
The next investor decisions hinge on Marvell’s share price, the approval process and whether Lumentum delivers its growth outlook. Merger delays, integration costs and weaker AI spending could change the investment case.
Financials and technicals
Charts through Oct 30, 2026. The session move above may reflect later news.
Technical setup and risks
October 30 completed close $840.7; SMA20 $921.82, SMA50 $922.9. Support reference $736–756 derives from October 22–23 lows; resistance $895–920 from October 14 and October 27–29 trading. A sustained close above resistance would repair the decline, while losing the prior low area would weaken it. The new merger makes Marvell’s share price and approval risk important alongside these chart levels.
AI-assisted research with source and calculation checks. Prices may be delayed. Technical charts use the stated completed session, which can precede the quoted intraday move. Educational information; investing involves risk.
